Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial

Journal of Child and Adolescent Psychopharmacology
M Van Bellinghen, C De Troch

Abstract

Risperidone, an antipsychotic agent with combined serotonin (5-HT2A) and dopamine (D2) receptor-blocking properties, is associated with fewer extrapyramidal side effects in adults than conventional neuroleptics. Approved in 1993 for the treatment of schizophrenia, recent studies have highlighted its potential in other conditions, such as the management of behavioral disturbances. This phase II, double-blind, placebo-controlled study evaluated the efficacy and tolerability of risperidone in the treatment of persistent behavioral disturbances in children with borderline intellectual functioning. Thirteen patients (6-14 years) with low IQ (66-85) were enrolled in and completed the 4-week study. Risperidone, in daily doses of > or = 0.01 mg/kg (mean dose at treatment endpoint = 0.05 mg/kg; mean total dose = 1.2 mg/day), was significantly more effective than placebo in improving Aberrant Behavioral Checklist (ABC) symptom cluster scores for irritation (p < 0.05) and hyperactivity (p < 0.01), Clinical Global Impression score (p < 0.05), the Visual Analogue Scale score for individual target symptom (p < 0.001), and Personal Assessment Checklist scores for social relationships (p < 0.05) and occupational attitudes (p < 0.05). In additi...Continue Reading

Citations

Sep 10, 2008·Journal of Neural Transmission·Christian FleischhakerAndreas Warnke
Mar 19, 2013·European Child & Adolescent Psychiatry·José María Martínez-OrtegaManuel Gurpegui
Oct 6, 2011·Journal of Autism and Developmental Disorders·Stephanie M SansoneDavid Hessl
Feb 28, 2013·The Psychiatric Quarterly·Bianca D Patel, Drew H Barzman
Sep 29, 2004·The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine·Nancy Rappaport, Christopher Thomas
Nov 13, 2002·Journal of Child and Adolescent Psychopharmacology·Nick C PatelM Lynn Crismon
Jan 15, 2005·Journal of Child and Adolescent Psychopharmacology·Jennifer Cheng-ShannonJames T McCracken
May 25, 2005·Journal of Child and Adolescent Psychopharmacology·Nick C PatelPeter S Jensen
Mar 9, 2007·Journal of Child and Adolescent Psychopharmacology·Rosa-Elena UlloaAlonso Fernández-Guasti
Jun 14, 2006·Journal of Child and Adolescent Psychopharmacology·Magali ReyesMarielle Eerdekens
Sep 9, 2006·Journal of Child and Adolescent Psychopharmacology·Gahan J PandinaRobert L Findling
Dec 15, 2011·Journal of Child and Adolescent Psychopharmacology·Lawrence Maayan, Christoph U Correll
Jan 25, 2003·Journal of the American Academy of Child and Adolescent Psychiatry·Sarah B SchurPeter S Jensen
Nov 5, 2011·Journal of Paediatrics and Child Health·Michael J DuhigJames G Scott
Feb 21, 2004·Annals of General Hospital Psychiatry·Konstantinos N FountoulakisGeorge Kaprinis
Jun 28, 2006·CNS Drugs·Oleg V Tcheremissine, Lori M Lieving
May 24, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·Nick C PatelPeter S Jensen
Feb 18, 2016·Journal of Child and Adolescent Psychopharmacology·Tina GurnaniJeffrey H Newcorn
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Suad Kapetanovic, George M Simpson
Jul 15, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Tamara PringsheimScott Patten
Nov 24, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Paz TorenAbraham Weizman
Jan 19, 2016·Current Opinion in Psychiatry·Na Young Ji, Robert L Findling
May 10, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alessandro ZuddasTatiana Usala
Jan 5, 2010·Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie·Jan FrölichManfred Döpfner
Apr 24, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Jorge L ArmenterosMarisabel Davalos
Dec 27, 2005·Human Psychopharmacology·Giampaolo La MalfaAlessandro Castellani
Aug 26, 2006·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Benjamin L Handen, Richard Gilchrist
Dec 20, 2013·American Journal of Medical Genetics. Part a·Anne WheelerDonald B Bailey
Dec 21, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·Jan CroonenberghsUNKNOWN Risperidone Disruptive Behavior Study Group
Jan 26, 2005·Research in Developmental Disabilities·Ashvind N SinghPeter Sturmey
Mar 15, 2006·Ambulatory Pediatrics : the Official Journal of the Ambulatory Pediatric Association·William O CooperWayne A Ray
Jan 18, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Peter Paul De Deyn, Jan Buitelaar
May 29, 2015·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·J ReekieM A Sabin
Jan 21, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Clement C ZaiJoseph H Beitchman
Mar 19, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Jiamei LianChao Deng
Jan 22, 2009·Thérapie·Claire ChevreuilDanièle Bentué-Ferrer
Sep 17, 2005·Journal of Psychopharmacology·Valérie J Fedorowicz, Eric Fombonne
Jan 26, 2006·The Annals of Pharmacotherapy·Nick C PatelAlan Shafer
Aug 10, 2017·The Cochrane Database of Systematic Reviews·Jik H LoyKarolina Stasiak
Jul 3, 2004·Journal of Clinical Psychopharmacology·Daniel J Safer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aphasia

Aphasia affects the ability to process language, including formulation and comprehension of language and speech, as well as the ability to read or write. Here is the latest research on aphasia.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here